ustekinumab,vedolizumab
takeda,janssen
['vedo', 'crohn', ' aa ', ' vedo', 'vedolizumab', 'ustekinumab', 'ibd']
 presented patients on anti-tnf agents have higher cmir following three doses of covid-19 vaccines and maintain the higher cmir at 6 months post dose
#ddw2023 
Official Twitter account of the University of Wisconsin Division of Gastroenterology and Hepatology, part of @uw_medicine. RTs, links ≠ endorsement